Biorestorative Therapies (NASDAQ:BRTX) Announces Quarterly Earnings Results, Meets Estimates

Biorestorative Therapies (NASDAQ:BRTX) announced its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38), Zacks reports. The firm had revenue of $0.01 million for the quarter. Biorestorative Therapies had a negative net margin of 3,308.09% and a negative return on equity of 192.82%.

Biorestorative Therapies Trading Down 9.4%

NASDAQ BRTX opened at $1.25 on Friday. Biorestorative Therapies has a 1-year low of $1.19 and a 1-year high of $2.55. The company has a 50 day moving average of $1.52 and a 200-day moving average of $1.60. The firm has a market cap of $9.98 million, a price-to-earnings ratio of -0.85 and a beta of -0.29.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Biorestorative Therapies in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biorestorative Therapies has a consensus rating of “Sell”.

About Biorestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.